Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loncastuximab Tesirine vs Idelalisib in R/R Follicular Lymphoma
NCT04699461Phase 2Terminated
- Sponsor
- ADC Therapeutics
- Start
- Nov 2021
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 10
01
Overview
A Phase 2 trial of loncastuximab tesirine in follicular lymphoma (FL), sponsored by ADC Therapeutics. Started Nov 2021; status: terminated.
02
Drugs
loncastuximab tesirine
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT04699461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04699461.